Interchangeability, Meetings And Access Among BsUFA III Priorities
Stakeholders Offer Specific Recommendations On US Biosimilar User Fee Program
Industry stakeholders have offered their views on key priorities for the BsUFA biosimilars user-fee program ahead of its reauthorization.
